Yunhee Choi

Yunhee Choi

Auto-generated profile, based on publicly available information

Yunhee Choi

Division of Medical Statistics, Medical Research Collaborating Center, Seoul National University Hospital, Seoul, Korea

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2017 in JAMA Dermatology
Verified
Journal Article
Open access
PDF file
KKKyu Han Kim
Kyu Han Kim
TCTae Hyun Choi
Tae Hyun Choi
YCYunhee Choi
Yunhee Choi
YPYoung Woon Park
Young Woon Park
KHKi Yong Hong
Ki Yong Hong
JJJAE HOON JEONG
JAE HOON JEONG
Infantile hemangioma (IH) is the most common tumor of infants and young children.1,2 Although small IH lesions typically do not cause problems, they often require treatment because of the site of occurrence and associated complications such as abnormal eye development or vision problems, airway obstruction, and bowel obstruction.3,4 Historically, steroids have been used as the primary treatment for IH.5,6 Steroids have been shown to be antiangiogenic in a number of in vitro settings and also have shown good therapeutic effects clinically. However, the use of steroids may lead to various complications including gastroesophageal reflux and growth disorders, although these complications are associated with long-term use and high dose.7 A type of anticancer drug or immunomodulator, interferon alfa, may be used for severe IH in cases where patients did not respond to steroids.8,9 However, interferon alfa also has several possible adverse effects, including fever, muscle pain, systemic myalgia, and in severe cases, liver damage, blood toxic effects, thyroid hormonal abnormality, and neurological and neurodevelopmental toxic effects.8 Because of concerns about these adverse effects, many guardians of pediatric patients prefer to wait rather than accept treatment.

1 January 2020 in Korean Journal of Radiology
Verified
Journal Article
Open access
SKSoo-Yeon Kim
Soo-Yeon Kim
NCNariya Cho
Nariya Cho
YCYunhee Choi
Yunhee Choi
SSSung Ui Shin
Sung Ui Shin
EKEun Sil Kim
Eun Sil Kim
WMWoo Kyung Moon
Woo Kyung Moon
Kim SY, et al. Korean J Radiol. 2020 Feb;21:e52. https://doi.org/10.3348/kjr.2019.0567

30 September 2022 in Korean Journal of Radiology
Verified
Journal Article
Open access
PDF file
HKHyo-Jin Kang
Hyo-Jin Kang
SLSang Min Lee
Sang Min Lee
JYJeong Hee Yoon
Jeong Hee Yoon
JYJeongin Yoo
Jeongin Yoo
YCYunhee Choi
Yunhee Choi
JHJoon Koo Han
Joon Koo Han
Kang HJ, et al. Korean J Radiol. 2022 Nov;23(11):1067-1077. https://doi.org/10.3348/kjr.2022.0388

3 September 2010 in BJU International
Verified
Journal Article
Open access
PDF file
UHU-Syn Ha
U-Syn Ha
THTae‐Kon Hwang
Tae‐Kon Hwang
YKYong June Kim
Yong June Kim
TOTae Hee Oh
Tae Hee Oh
YJYoun Soo Jeon
Youn Soo Jeon
SBSeok-Soo Byun
Seok-Soo Byun
Study Type – Therapy (case series) Level of Evidence 4 What’s known on the subject? and What does the study add? Laparoscopic radical nephrectomy (LRN) can be performed by a retroperitoneal approach with similar efficacy compared to the transperitoneal approach. However, the oncological acceptance of LRN has been based on studies which have been carried out primarily by transperitoneal approach, and oncological results of the retroperitoneal approach alone are lacking. Our study confirmed that retroperitoneal laparoscopic radical nephrectomy is oncologically‐equivalent to transperitoneal approach in homogeneous group with the final pathological diagnosis of clear cell RCC. OBJECTIVE: To investigate the oncological efficacy of retroperitoneal laparoscopic radical nephrectomy (RLRN) compared with transperitoneal laparoscopic radical nephrectomy (TLRN) for the management of clear‐cell renal cell carcinoma (RCC). PATIENTS AND METHODS: With emphasis on survival and disease recurrence, a retrospective analysis was made of 580 patients who underwent TLRN (472 patients) or RLRN (108 patients) at 23 institutions between January 1997 and December 2007. Inclusion criteria were clear‐cell RCC, stage pT1 to pT2 without any nodal involvement, and metastasis. Overall survival and recurrence‐free survival curves were estimated using the Kaplan–Meier method. To assess the association between the surgical approach and survival outcomes, Cox proportional hazard models were constructed. RESULTS: The median follow‐up was 30 months in the TLRN group and 35.6 months in the RLRN group. Both groups were comparable regarding age, gender, body mass index (BMI), Fuhrman’s grade, size of tumours and stage. Kaplan–Meier curves and the log‐rank test showed no significant difference between the TLRN and RLRN groups in 5‐year overall (92.6% vs 94.5%; P = 0.669) and recurrence‐free survival (92.0% vs 96.2%; P = 0.244). In a Cox regression model with age, gender, Eastern Cooperative Oncology Group performance status, BMI, nuclear grade and T‐stage adjusted variables, no significant difference was found between the two surgical approaches. CONCLUSION: The present study is the largest oncological analysis for laparoscopic radical nephrectomy (LRN) comparing transperitoneal and retroperitoneal approaches. The data from it provide the objective evidence to suggest similar oncological outcomes for both approaches to LRN.

1 January 2019 in Journal of Korean Medical Science
Verified
Journal Article
Open access
HHHyunsook Hong
Hyunsook Hong
SHSeokyung Hahn
Seokyung Hahn
YCYunhee Choi
Yunhee Choi
MJMyoung-Jin Jang
Myoung-Jin Jang
SKSunhee Kim
Sunhee Kim
HKHee-Soo KIM
Hee-Soo KIM
Hong H, et al. J Korean Med Sci. 2019 Apr;34(15):e124. https://doi.org/10.3346/jkms.2019.34.e124